New Tech Now Available

High Affinity Antibody for the Treatment of Pertussis (Whooping Cough) and Neutralization of Pertussis Toxin

Researchers at The University of Texas have engineered a novel antibody that specifically recognizes the pertussis toxin (PTx) for the treatment of disease and passive immunity. This is achieved by engineering a "humanized" antibody with an enhanced ability to recognize and bind the PTx, thus enabling the white blood cells to effectively neutralize the threat.

Video

Learn about the OTC

Colloquium on Commercialization

Goodenough and Heller
honored as 2011
Inventors of the Year

[ Goodenough and Heller ]

Dr. John Goodenough and Dr. Adam Heller were honored as 2011 Inventors of the Year at a ceremony and reception Dec. 6.
Read about it in "Tower Talk" »

Commercialization news

UT and SunGard team to create cloud computing center

Cloud computing

The Cloud Computing Research Center will allow UT's Computer Science department and SunGard to work together to pursue research initiatives to solve problems in the cloud-computing field....
Read the complete story »

Colloquium on Commercialization

Licensing and
Corporate Partnering

Nov. 9—Speakers from Abbott, Bracewell & Giuliani, and Dell presented in the second program of the Colloquium on Commercialization, a series aimed at UT researchers.
Read about "Licensing and Corporate Partnering" »